Related Experiment Video

Updated: May 14, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma

Xiangmin Tong1, Xuewu Zhang, Jian Fan

  • 1Department of Hematology, First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.

Cancer Biology & Therapy
|January 31, 2013
PubMed
Abstract

Insights

The RON receptor tyrosine kinase drives Burkitt lymphoma (BL) progression and cancer development. Inhibiting RON can decrease tumor growth by promoting cell death and halting cell cycle, making it a potential therapeutic target for BL.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Aberrant expression of the RON receptor tyrosine kinase is linked to tumor progression and carcinogenesis.
  • Understanding RON's role in Burkitt lymphoma (BL) is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the role and functional mechanisms of RON in Burkitt lymphoma.
  • To evaluate RON as a potential therapeutic target for BL.

Main Methods:

  • Western blot and immunohistochemistry were used to assess RON expression in BL cell lines and tissues.
  • Correlation between RON expression and Epstein-Barr virus (EBV) infection was examined.
  • In vitro and in vivo studies using anti-RON monoclonal antibody (mAb) assessed effects on cell viability, proliferation, apoptosis, cell cycle arrest, and tumor growth.

Main Results:

  • High frequency of RON expression observed in BL tissues, strongly correlating with EBV positivity.
  • Downregulation of RON significantly reduced cell proliferation and colony formation by inducing apoptosis and cell cycle arrest in Raji cells.
  • In vivo studies confirmed that RON knockdown inhibits the tumorigenic potential of BL cells.

Conclusions:

  • RON functions as an oncogene in the carcinogenesis and progression of Burkitt lymphoma.
  • RON represents a promising therapeutic target for intervention in BL.
Keywords:
Burkitt lymphomaRONmechanismmonoclonal antibodyoncogenic signal transductionreceptor tyrosine kinasetargeted therapy

More Related Videos

Functional Characterization of Endogenously Expressed Human RYR1 Variants07:59

Functional Characterization of Endogenously Expressed Human RYR1 Variants

Published on: June 9, 2021

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...